Illumina Sues Oxford Nanopore for Patent Infringement
News Feb 24, 2016
The lawsuits were filed concurrently with the U.S. International Trade Commission and in the U.S. District Court for the Southern District of California. Illumina is seeking all available remedies.
The lawsuits are based on U.S. Patent Nos. 8,673,550 and 9,170,230, which are entitled “MSP NANOPORES AND RELATED METHODS.” Illumina has exclusively licensed the patents in the field of nucleic acid sequencing from the UAB Research Foundation and the University of Washington. The lawsuits focus on ONT’s MinION and PromethION devices.
Illumina has made substantial investments to obtain licenses and develop the nanopore sequencing technology invented by researchers at the University of Alabama at Birmingham and University of Washington. Illumina filed the lawsuits to protect its investment and patent rights in this technology.
CRISPR Diagnostics Could Detect Any Disease on a Paper StripNews
A nucleic acid-detecting diagnostics platform that harnesses the gene editing technology CRISPR was announced today by the newly-launched Mammoth Biosciences, which says the technology could change how we diagnose disease.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018